Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Orthopedics Clinical Trials

Santen eyes uveitis market with top-line sirolimus data

This article was originally published in Scrip

Executive Summary

Japanese eye company Santen has released positive top-line data for the first Phase III trial of its sirolimus-based uveitis treatment.

You may also be interested in...



Keeping Track: So. Much. News.

The latest drug development news and highlights from our US FDA Performance Tracker.

Keeping Track: Breakthroughs Dominate 2017 Novel Agents; US FDA Approves Rydapt, Alunbrig, Tymlos, Brineura

The latest drug development news and highlights from our FDA Performance Tracker.

Olema Boosts Its Partnering Position With SERD Combo Data

Scrip caught up with Olema CEO Sean Bohen ahead of a crucial combination data readout due this month for its novel SERD, palazestrant, which it hopes will put the drug on the path to a $10bn-plus breast cancer market.

Table

View full table

Topics

Related Companies

Tags:
Orthopedics Clinical Trials
Latest Headlines

Finance Watch: Lilly, Fosun Reveal Strategic Investments In Start-Ups, Growth-Stage Firms

Pfizer’s Mixed Readout Places Doubt On Oral GLP-1 For Obesity

Fueled By Lilly And Novo Buy-Outs, Forbion Looks To Make Most Of ‘Buyers’ Market’

Altimmune Regains Some Momentum

See All
UsernamePublicRestriction

Register

SC024973

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By